Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 8/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.37 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945007 | 0.82 | NPC1 (0.40) | HCAR3MAPT | |
| SCHEMBL670410 | 0.80 | HCAR3 (0.55) | HCAR3CDC25BMAPTAKR1C2AKR1C1 | |
| SCHEMBL21808102 | 0.80 | HCAR3 (0.58) | HCAR3CDC25BMAPTAKR1C2AKR1C1 | |
| SCHEMBL1965597 | 0.78 | NPSR1 (0.49) | HCAR3CDC25BMAPTAKR1C2AKR1C1 | |
| SCHEMBL28644617 | 0.74 | HCAR3 (0.41) | HCAR3CDC25BMAPTAKR1B1 | |
| SCHEMBL28644615 | 0.74 | HCAR3 (0.41) | HCAR3CDC25BMAPTAKR1B1 | |
| SCHEMBL29061680 | 0.74 | HCAR3 (0.58) | HCAR3CDC25BMAPTAKR1C2AKR1C1 | |
| SCHEMBL670578 | 0.73 | DTYMK (0.46) | MAPTAKR1C2AKR1C1ESPL1TSHR | |
| SCHEMBL9945039 | 0.73 | HCAR3 (0.39) | HCAR3CDC25BMAPTAKR1C2AKR1C1 | |
| SCHEMBL2443339 | 0.72 | TSHR (0.51) | MAPTAKR1C2AKR1C1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | HCAR3 228/4885CDC25B 1778/4885MAPT 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.